Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 4, 2007, Pages 511-517

  Warrington, S ^a   Baisley, K ^a   Lee, D ^a   Lomax, K ^b   Delemos, B ^c   Boyce, M ^a   Morocutti, A ^d  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b EISAI INC   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

^d EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PANTOPRAZOLE; RABEPRAZOLE;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HELICOBACTER PYLORI; HUMAN; INDIGESTION; MALE; NAUSEA; NIGHT; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED;

EID: 33846649559     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03196.x     Document Type: Article

References (10)

1. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
2. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 1): 3-7.
3. Orr WC. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 2005; 17: 113-20.
4. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
5. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7.
6. Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol 2003; 9: 2583-6.
7. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
8. Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-8.
9. Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 931-6.
10. National Institute of Clinical Excellence (NICE). Clinical guideline on management of dyspepsia in adults in primary care. August 2004.